Merck & Co’s Keytruda Gets Foot In The Door For First-Line Gastric Cancer
Executive Summary
Results presented as ASCO from the mixed KEYNOTE-062 study suggest a place for pembrolizumab in first-line gastric cancer but data from other ongoing trials will be needed to support filings amid looming competition from Opdivo.
You may also be interested in...
ESMO: BMS’s Opdivo Edges Merck & Co’s Keytruda In First-Line Advanced Gastroesophageal Cancers
A new frontier for IO therapies in gastric/gastroesophageal cancers is opening up on positive data for two leading checkpoint inhibitors in first-line advanced disease where BMS’s Opdivo looks likely to have an advantage over Merck & Co’s Keytruda.
Commercial Fallout From Merck's Failed Keytruda Gastric Cancer Trial May Be Limited
Merck's KEYNOTE-061 gastric cancer study is the latest example of a checkpoint inhibitor failing in Phase III after accelerated approval.
Pfizer/Merck KGAA's Bavencio Gastric Cancer Failure Not As Bad As It Seems
Disappointing outcome for the companies' PD-L1 inhibitor avelumab in late-stage gastric cancer may not have implications for the drug in more valuable indications, like lung cancer.